- Investing Ideas
- /
- German Pharmaceuticals & Biotech Potentially Undervalued Companies
German Pharmaceuticals & Biotech Potentially Undervalued Companies
UPDATED May 24, 2023
Companies with a Value score of at least 3, ordered by Value score
450 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2DTAmneal Pharmaceuticals | US$2.04 | 10.9% | -32.9% | US$687.3m | US$3.13 | PB1.2x | S3.6% | 0% | ||
| BRMBristol-Myers Squibb | US$60.10 | -1.8% | -17.1% | US$137.5b | US$72.56 | PE18.8x | E15.4% | 3.5% | ||
| PIGPerrigo | US$30.31 | -0.9% | -17.7% | US$4.4b | US$44.77 | PB0.9x | E102.7% | 3.4% | ||
| RV6Charles River Laboratories International | US$185.40 | 2.6% | -10.5% | US$10.2b | US$235.99 | PE20.1x | E14.1% | n/a | ||
| MRKMerck KGaA | €165.80 | 2.8% | -5.5% | €71.3b | €203.72 | PE22.2x | E10.6% | 1.3% | ||
| 354Collegium Pharmaceutical | US$21.20 | 1.9% | 44.2% | US$797.1m | US$31.84 | PS1.5x | E25.3% | n/a | ||
| 940Euroapi | €10.04 | -1.0% | -24.2% | €954.5m | €14.78 | PB0.9x | E38.9% | n/a | ||
| PMRAPharma Mar | €35.76 | 2.8% | -48.5% | €643.5m | €65.70 | PE21.7x | E27.3% | 1.9% | ||
| PHGNPharming Group | €1.17 | 7.8% | 53.1% | €762.0m | €1.97 | PS4.1x | E65.4% | n/a | ||
| CVGCSPC Pharmaceutical Group | HK$0.84 | -7.8% | -2.3% | HK$85.9b | HK$1.35 | PE12.7x | E7.1% | 2.9% | ||
| E2ZAlmirall | €8.34 | -0.2% | -19.5% | €1.5b | €11.68 | PS1.7x | E47.7% | 2.2% | ||
| 04KKnight Therapeutics | CA$3.16 | -2.5% | -18.6% | CA$518.0m | CA$4.10 | PS1.7x | E73.9% | n/a | ||
| BRMBristol-Myers Squibb | US$61.00 | -1.3% | -16.4% | US$137.5b | US$73.65 | PE18.8x | E15.4% | 3.5% | ||
| GEKAGenomma Lab Internacional. de | Mex$0.76 | -6.8% | -19.7% | Mex$14.7b | Mex$1.11 | PE10.4x | E15.6% | 2.6% | ||
| BONBoiron | €38.60 | 0% | -7.4% | €681.7m | €47.68 | PE15.3x | E9.2% | 2.8% | ||
| MRKMerck KGaA | €165.35 | 3.4% | -5.5% | €71.3b | €203.17 | PE22.2x | E10.6% | 1.3% | ||
| 2M7CChina Medical System Holdings | HK$1.42 | 0% | 16.4% | HK$29.3b | HK$2.01 | PE8.1x | E7.9% | 5.0% | ||
| RIG2Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt | Ft22.36 | 2.1% | 20.9% | Ft1.5t | Ft27.76 | PE9.7x | E17.8% | 4.7% | ||
| B6ESwedish Orphan Biovitrum | kr19.93 | -2.0% | -0.6% | kr68.5b | kr24.68 | PE21.7x | E20.7% | n/a | ||
| DVLAlliance Pharma | UK£0.71 | -10.1% | -45.4% | UK£336.4m | UK£1.04 | PE359.4x | E39.7% | 2.9% | ||
| DMPDermapharm Holding | €45.74 | 1.6% | -4.3% | €2.5b | €57.25 | PE16.8x | E1.8% | 2.3% | ||
| J7ZJazz Pharmaceuticals | US$118.15 | -2.2% | -17.3% | US$8.3b | US$185.16 | PS2.2x | E20.4% | n/a | ||
| TEHPAvid Bioservices | US$14.10 | 0.7% | 20.5% | US$946.3m | US$20.63 | PE8.2x | E-13.6% | n/a | ||
| N4CNParatek Pharmaceuticals | US$1.58 | -5.3% | -1.0% | US$100.8m | US$4.78 | PE-1.5x | E73.9% | n/a |